Thus, the accumulating evidence suggests a potential risk of triggering disorders of coagulation-fibrinolysis system in association with ICI therapy within blood vessels; T cell activation by anti-PD-1/PD-L1 monoclonal antibody therapies may lead to promoting TF synthesis in monocytes/macrophages, which could result in triggering disorders of coagulation-fibrinolysis system such as DVT, PTE, and Trousseau’s syndrome in advanced cancer patients (Figure 6A). Here, PDCD1 is linked to cancer.